Empire Petroleum Corp (EP) Stock News

Investec Bank plc, acting as Advisor and Broker to Gooch & Housego plc, disclosed public dealing in ordinary shares of Gooch & Housego plc on 7th August 2026. The disclosure shows purchases of 108,299 shares at 1220 pence per unit and sales of 108,017 shares at prices ranging from 1220 to 1222.5 pence per unit, filed under Rule 8.5 of the Takeover Code.

Investec Bank Plc, acting as Advisor & Joint Broker to Advanced Medical Solutions Group Plc, disclosed public dealing in the company's ordinary shares on August 7, 2026. The bank purchased 9,541 shares and sold 147,431 shares, both at a price of 281.25 pence per share, in accordance with Takeover Code Rule 8.5 requirements.

A securities fraud class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly making materially false statements about product demand. The company allegedly used undisclosed discount programs to inflate handpiece unit sales, resulting in overstocking. PROCEPT's stock fell over 18% on February 25, 2026, when the company revealed that handpiece sales had consistently exceeded procedures. Investors have until September 22, 2026, to seek lead plaintiff status.

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against PROCEPT BioRobotics Corporation. The lawsuit alleges that PROCEPT made materially false statements regarding its handpiece unit sales and revenues by utilizing an undisclosed discount program that artificially inflated sales figures. The company allegedly accumulated over 10,000 excess units in field inventory and was unable to achieve its 2025 guidance. The lead plaintiff deadline is September 22, 2026.

PROCEPT BioRobotics faces a securities class action lawsuit for allegedly failing to disclose material information about excess handpiece inventory and inflated sales figures during the Class Period (February 28, 2024 - February 25, 2026). The company is accused of misleading investors about U.S. handpiece sales that exceeded procedures, resulting in over 10,000 units of excess inventory that would cause significant revenue declines. Investors with losses exceeding $100,000 have until September 22, 2026 to file lead plaintiff applications.

Kaplan Fox & Kilsheimer LLP has filed class action lawsuits against PROCEPT BioRobotics Corporation for allegedly using undisclosed discount programs that artificially inflated handpiece unit sales and revenues during the Class Period (February 28, 2024 - February 25, 2026). The firm is also pursuing cases against Hub Group, Inc. and investigating potential securities violations at Alignment Healthcare, Inc. Investors with losses are encouraged to contact the firm before respective deadlines.

Grabar Law Office has filed federal securities fraud class action investigations against four companies: Erasca for misleading statements about its ERAS-0015 drug candidate and undisclosed patent risks; Insulet for defective manufacturing controls leading to voluntary product corrections; Power Solutions for overstating sales demand and understating manufacturing costs; and PROCEPT BioRobotics for using undisclosed discount programs that artificially inflated sales and created excess inventory. Shareholders who purchased shares during specified periods are eligible to seek damages and corporate reforms.

Investec Bank plc, acting as advisor and broker to Gooch & Housego plc, disclosed public dealing in ordinary shares of Gooch & Housego on August 6, 2026. The bank purchased 3,348 shares at prices between 1225 pence and sold 5,166 shares at the same price range. The disclosure was filed under Rule 8.5 of the Takeover Code.

Klépierre, Europe's leading shopping mall operator, announced the release of its first-half 2026 financial report on August 6, 2026. The company raised its full-year 2026 guidance, projecting EBITDA to reach a minimum of €1,150 million, driven by strong execution in a dynamic retail market and organic growth.

A class action lawsuit has been filed against PROCEPT BioRobotics Corporation alleging securities fraud. The company allegedly failed to disclose an extensive discount program that artificially inflated handpiece sales and revenues between February 2024 and February 2026. The undisclosed practices led to excess field inventory exceeding 10,000 units and significant stock price declines following quarterly earnings announcements. Shareholders who purchased PROCEPT securities during the class period have until September 22, 2026 to file a lead plaintiff motion.

Investec Bank plc, acting as Joint Broker to Gamma Communications Plc, disclosed public dealing in ordinary shares of Gamma Communications on August 4, 2026. The bank purchased and sold 82,076 ordinary shares at prices ranging from 960p to 961.67p per unit.

Investec Bank Plc, acting as Advisor & Joint Broker to Advanced Medical Solutions Group Plc, disclosed public dealing in the company's ordinary shares on August 4, 2026. The bank purchased 609,558 shares at prices between 279.75-280.25 and sold 685,425 shares at prices between 280.00-280.50, indicating active market-making activity during the offer period.

Investec Bank plc, acting as Advisor and Broker to Gooch & Housego plc, disclosed public dealing in ordinary shares of Gooch & Housego plc on August 4, 2026. The bank purchased 397,945 shares and sold 396,287 shares at prices ranging between 1222 and 1227.5 per unit, in compliance with Takeover Code Rule 8.5 disclosure requirements.

Grabar Law Office has launched investigations into potential securities fraud and fiduciary duty breaches at four major companies: Erasca (ERAS) for misleading statements about its ERAS-0015 drug candidate and undisclosed patent risks; Insulet (PODD) for defective manufacturing controls leading to voluntary product corrections; Power Solutions International (PSIX) for overstating sales demand and understating manufacturing costs; and PROCEPT BioRobotics (PRCT) for using undisclosed discount programs that artificially inflated sales figures and created excess inventory.

Rosen Law Firm has filed class action lawsuits against PROCEPT BioRobotics Corporation for allegedly making materially false statements regarding sales practices. The lawsuit claims PROCEPT used undisclosed discount programs to artificially inflate handpiece unit sales and revenues, created excess inventory of over 10,000 units, and provided unrealistic 2025 guidance. Investors who purchased stock between February 28, 2024 and February 25, 2026 may be eligible for compensation. The deadline to serve as lead plaintiff is September 22, 2026.

Robbins Geller has filed a class action lawsuit against PROCEPT BioRobotics Corporation, alleging that the company and its executives made materially false and misleading statements regarding undisclosed discount programs that artificially inflated sales figures and created excess field inventory. The lawsuit covers investors who purchased PRCT stock between February 28, 2024 and February 25, 2026. Multiple stock price declines followed earnings announcements revealing lower-than-expected handpiece sales and inventory management issues.

Investec Bank plc, acting as Advisor & Joint Broker to Advanced Medical Solutions Group plc, disclosed public dealing in the company's ordinary shares on 31st July 2026. The bank purchased 358,730 shares and sold 431,803 shares at prices between 280.00 and 280.25 per unit.

Rosen Law Firm has filed a securities class action lawsuit against PROCEPT BioRobotics Corporation on behalf of investors who purchased common stock between February 28, 2024 and February 25, 2026. The lawsuit alleges that PROCEPT made materially false statements regarding its handpiece unit sales and revenues by utilizing an undisclosed discount program that artificially inflated sales figures and created excess inventory of over 10,000 units. The firm claims the company's 2025 guidance lacked a reasonable factual basis. Investors must move the court by September 22, 2026 to serve as lead plaintiff.

A class action lawsuit has been filed against PROCEPT BioRobotics Corporation alleging the company issued materially false statements regarding its handpiece unit sales and revenues. The complaint claims PROCEPT used an undisclosed discount program to artificially inflate sales figures, created excess field inventory of over 10,000 units, and failed to disclose material risks. The lead plaintiff deadline is September 22, 2026.

FORVIA announced its H1 2026 financial results, reporting margin expansion and strong net cash flow generation. The company confirmed its full-year guidance, demonstrating progress on its IGNITE strategic roadmap. The financial report has been filed with French financial authorities and is available on the company's investor relations website.

PROCEPT BioRobotics faces a securities class action lawsuit for allegedly failing to disclose material information about excess handpiece inventory and inflated sales figures during the Class Period (February 28, 2024 - February 25, 2026). Investors with losses exceeding $100,000 have until September 22, 2026 to file lead plaintiff applications.

Pixalate's June 2026 OpenEPG™ Index reveals that Reality, News, and Sport genres account for 81% of large-screen CTV open programmatic ad spend. Food Network dominates CTV with 34% of ad spend, while News content captures 64% of mobile streaming TV ad spend. NBA's Hardwood Classics ranked #1 on CTV, and BET's Being Mary Jane led mobile rankings for the second consecutive month.

Investec Bank plc, acting as Joint Broker to Gamma Communications Plc, disclosed dealings in ordinary shares of Gamma Communications on 29th July 2026. The exempt principal trader purchased and sold 40,642 ordinary shares at prices ranging from 61.5 to 977.596 per unit. The disclosure was filed under Rule 8.5 of the Takeover Code.

Investec Bank plc, acting as Advisor and Broker to Gooch & Housego plc, disclosed public dealing in ordinary shares of Gooch & Housego plc on 29th July 2026. The bank purchased 11,800 shares and sold 15,000 shares at prices ranging between 1220 pence per unit, in compliance with Takeover Code Rule 8.5 disclosure requirements.

Investec Bank plc, acting as Advisor & Joint Broker to Advanced Medical Solutions Group Plc, disclosed public dealing in the company's ordinary shares on 29th July 2026. The bank purchased 419,640 shares at prices between 280.00-280.25 per unit and sold 550,000 shares at 280.00 per unit. The disclosure was made in compliance with Rule 8.5 of the Takeover Code.

Onco360, the nation's leading independent specialty pharmacy, has been selected as a pharmacy partner by Rigel Pharmaceuticals for VEPPANU (vepdegestrant), an FDA-approved PROTAC estrogen receptor degrader for treating ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. In the Phase 3 VERITAC-2 trial, vepdegestrant demonstrated a 43% reduction in disease progression or death risk compared to fulvestrant in patients with ESR1 mutations.

Investec Bank plc, acting as Advisor & Joint Broker to Advanced Medical Solutions Group Plc, disclosed public dealing in ordinary shares on 28th July 2026. The bank purchased 1,000,509 shares and sold 1,034,688 shares at prices ranging between 280.12p and 280.25p per unit.

Investec Bank plc, acting as Advisor and Broker to Gooch & Housego plc, disclosed public dealing in ordinary shares of Gooch & Housego plc on 28th July 2026. The exempt principal trader purchased 56,109 shares and sold 51,842 shares at prices ranging between 1220-1225 per unit.

Investec Bank plc, acting as Joint Broker to Gamma Communications Plc, disclosed dealings in Gamma Communications ordinary shares on 28th July 2026. The exempt principal trader purchased and sold 177,395 ordinary shares each at a price of 979.5954 per unit. The disclosure was filed on 29th July 2026 in compliance with Rule 8.5 of the Takeover Code.

PROCEPT BioRobotics faces a securities class action lawsuit for failing to disclose material inventory issues. The company revealed on February 25, 2026 that handpiece sales had materially exceeded procedures since Q1 2023, resulting in over 10,000 units of excess field inventory. This disclosure caused the stock to decline approximately 18% in two days, from $27.84 to $22.69 per share. Investors who purchased shares between February 28, 2024 and February 25, 2026 can file lead plaintiff applications by September 22, 2026.